A SARS-CoV-2 nanobody that can bind to the RBD region may be used for treatment in COVID-19 in animals

Abstract

Coronavirus disease 2019 (COVID-19) caused by an infectious virus, severe acute respiratory syndrome-coronavirus 2 (SARS-CoV-2), poses a threat to the world. The suitable treatments must be identified for this disease in animals. Nanobody have therapeutic potential in the COVID-19. In this study, SARS-CoV-2 Spike RBD protein was used to make the nanobody. Nanobodies binding to the SARS-CoV-2 Spike RBD protein was obtained. Interestingly, the nanobody could bind to SARS-CoV-2 Spike S protein and RBD protein at the same time. Nanobodies were validated with a neutralizing antibody detection kit. The use of pseudoviruses confirmed that nanobodies could prevent pseudoviruses from infecting cells. We believe the nanobody are very valuable and could be used in the treatment of COVID-19. SARSCoV-2 nanobodies can be rapidly mass-produced from microorganisms to block SARS-CoV-2 infection in vitro and in vivo with preventive and therapeutic effects.

A scalable and high yielding SARS-CoV-2 spike protein receptor binding domain production process

“…Upon the application of streptavidin labeled peroxidase the products were visualized. Both materials contained a protein marginally larger than 28 kDa, consistent with the molecular weight determined for other expressions of SARS-CoV-2 Spike Protein RBD in HEK293 cells [ 44 ].

Fig.

…”

A Review of Potential Therapeutic Strategies for COVID-19

“…The complex can neutralize SARS-CoV-2 and has preventive and therapeutic effects on virus infection [61,62]. Wu et al prepared a SARS-CoV-2 nanobody that can simultaneously bind to the RBD to block human infection [63].…”